Market Access and Health Economics Team Buildout
Regulatory approval decides whether a therapy can be sold. Market access decides whether anyone will pay for it, and that is a separate program with separate evidence requirements, separate buyers and a separate vendor ecosystem. The moment a company staffs it is unusually detectable, because health economics, outcomes research, payer strategy and pricing and reimbursement roles are explicitly titled and rarely filled speculatively. Avina detects that hiring alongside the pipeline events that cause it, which is what separates a company building an access function from a company that has had one for a decade.
Why a Market Access Buildout Is a Buying Signal for Sales Teams
Every therapeutic or device company reaches a point where the science stops being the constraint and the payer becomes it. The transition is abrupt, it is driven by pipeline stage rather than company size, and it creates a burst of purchasing across data, evidence, modeling and services within a compressed period. The requirement is structural. A payer deciding whether to cover a therapy is not evaluating the pivotal trial on its own terms. It wants to know what the therapy displaces, what it costs relative to the current standard of care, what happens to total cost of care across a covered population, how the treated population behaves outside a controlled trial, and what the budget impact looks like over the contract period. None of those questions are answered by the registration package. They are answered with real-world data, health economic models, comparative evidence and a value dossier, and the company needs all of them before the first payer conversation rather than after it. That creates a specific and expensive shopping list. Claims, electronic health record and registry data have to be licensed, and the license terms are negotiated against specific research questions. Economic models, cost-effectiveness and budget impact analyses have to be built and validated. Real-world evidence studies have to be designed and run, frequently by an external partner. Value dossiers and payer materials have to be produced under medical, legal and regulatory review. Health technology assessment submissions in markets that require them have their own formats and timelines. And in the United States, patient support, hub services and reimbursement assistance have to exist on the day of launch because access friction at the pharmacy counter destroys uptake in the first quarter. The triggers are legible from outside. A trial advancing to late stage sets the clock, because access evidence has to be planned years before approval rather than after it. A regulatory submission concentrates it. An approval makes it urgent. An in-licensing deal or pipeline acquisition creates a commercial asset in a company that may have had no commercial function at all. A pricing controversy or a payer coverage restriction on a comparable therapy changes the evidence bar for everyone in the category. And the arrival of a chief commercial officer or a first head of market access signals that the company has decided the transition is now. The buildout is unusually purchase-dense for its headcount. A market access function of a dozen people routinely commits to data licenses, research partnerships, modeling work and services contracts that dwarf its salary line.
How Does Avina Detect Market Access Buildouts?
Avina, an AI-powered GTM platform, detects the access hiring, the pipeline events that force it and the vendor relationships already in place. Hiring is the clearest evidence and unusually specific in this field. Health economics and outcomes research directors and scientists, real-world evidence leads, market access and payer strategy directors, pricing and reimbursement managers and value and access marketing roles are explicitly titled, rarely ambiguous and almost never posted without a funded program behind them. A first such role at a company that has only had clinical and regulatory functions is one of the strongest single indicators in life sciences commercial buying. Supporting roles identify scope: biostatisticians and epidemiologists naming claims or registry data indicate real-world studies being planned internally, field medical roles naming payer audiences indicate a payer-facing medical strategy, and patient access and reimbursement services roles indicate launch preparation. Pipeline stage is monitored from trial registries, regulatory announcements and filings. Advancement to late-stage trials, primary endpoint readouts, regulatory submissions, approval decisions and label expansions are detected with dates attached, and mapped to the access planning window that precedes each one. Asset events are tracked. In-licensing deals, pipeline acquisitions, option exercises and partnership announcements create commercial assets, sometimes in companies with no commercial infrastructure, which is a particularly high-value pattern. Public communications are read for access signals. Investor materials and filings describing commercial readiness, pricing strategy, reimbursement risk, payer coverage progress and access commentary indicate where a company believes its constraint lies, and companies increasingly disclose access risk explicitly. Evidence activity is monitored. Health technology assessment submissions, payer coverage decisions, published value evidence and conference presentations establish whether a program is generating evidence already and in which markets. Vendor relationships are identified from listings naming a data provider or platform, publication acknowledgements, partnership announcements and conference disclosures, which establishes both incumbency and gaps across data, modeling and services. Each account is enriched with the hiring detected, the pipeline stage and dates, the asset events, the evidence activity and the vendor relationships observed, then matched against your ICP filters.
What Happens When a Market Access Signal Fires?
Avina scores on stage against capability. A company with a late-stage asset, a first market access or health economics hire and no real-world data or modeling relationship detected scores at the top of the model, because the evidence requirement has a date and the capability is being assembled from nothing. A company that has just in-licensed or acquired a commercial-stage asset scores next, because it has inherited a launch obligation on someone else's timeline. A company with an established access function scores lower and is routed toward specific expansions: additional data assets, new geographies and health technology assessment markets, label expansion evidence or post-launch outcomes commitments. Timing is governed by the development calendar and runs earlier than most people expect. Access evidence planning happens around the start of late-stage development, because retrospective data work and model development take time that a launch date will not forgive. Regulatory submission concentrates the work, since the value dossier and payer materials have to be ready before approval rather than after. The year before launch is the densest purchasing period. And post-launch, coverage restrictions and payer pushback create a second wave of evidence spending that is reactive and fast. Routing follows a commercial and medical committee. The head of market access or value and access owns payer strategy and is usually the economic buyer for data and modeling. The head of health economics and outcomes research owns evidence generation and evaluates research partners directly. The chief commercial officer owns launch readiness and the budget. Medical affairs leadership owns publications, field medical and the scientific exchange with payers. Regulatory participates where evidence requirements overlap with label claims. And at smaller companies the chief executive or chief medical officer is a direct participant, because the access decision is a company-level bet rather than a functional one. Contacts are enriched with verified emails, phone numbers and LinkedIn profiles through waterfall enrichment across market access, health economics, medical affairs and commercial leadership. Reps receive a Slack alert naming the company, the pipeline stage and dates detected, the access hiring observed, the evidence activity and the vendor relationships identified. Salesforce and HubSpot records carry the trigger date so sequences fire while the evidence plan is being written rather than after the data license has been signed. Qualified accounts can be auto-enrolled into Outreach or Salesloft sequences matched to the gap: real-world data licensing across claims, electronic health records and registries, real-world evidence study design and execution, health economic and budget impact modeling, value dossier and payer communication development, health technology assessment submission support, pricing and contracting analytics, patient support and reimbursement hub services, and the medical communications and publication planning work companies buy alongside the data because evidence that is never published does not move a coverage decision.
Start Tracking Market Access Buildouts With Avina
A first health economics hire against a late-stage asset is a data and evidence budget being committed this year. Activate this signal in Avina's Signals Library. Every plan includes a 7-day free trial with no credit card required.